Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 4/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.50 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.47 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | PARP1 | P09874 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | BLM | P54132 | 1/20 | 0.45 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Adipic Acid SCHEMBL1648545 | 0.96 | CYP2C19 (0.58) | CYP2C19CYP1A2CYP2C9CYP17A1NAPRT | |
| Succinic Acid SCHEMBL1650227 | 0.92 | CYP17A1 (0.53) | CYP2C19CYP1A2CYP2C9CYP17A1NAPRT | |
| SCHEMBL1649541 | 0.88 | CYP1A2 (0.55) | CYP2C19CYP1A2CYP2C9CYP17A1NAPRT | |
| SCHEMBL1648991 | 0.87 | CYP17A1 (0.49) | CYP2C19CYP1A2CYP2C9CYP17A1NAPRT | |
| Carbamic Acid SCHEMBL29194228 | 0.83 | NAPRT (0.61) | CYP2C19CYP1A2CYP2C9CYP17A1NAPRT | |
| SCHEMBL8582840 | 0.83 | NAPRT (0.59) | CYP2C19CYP1A2CYP2C9CYP17A1NAPRT | |
| SCHEMBL44995 | 0.83 | — | — | |
| Chloroacetic Acid SCHEMBL1650215 | 0.82 | CYP17A1 (0.51) | CYP2C19CYP1A2CYP2C9CYP17A1NAPRT | |
| SCHEMBL5850399 | 0.82 | HDAC3 (0.60) | CYP2C19CYP1A2CYP2C9NAPRTCYP3A4 | |
| Benzamide SCHEMBL28868460 | 0.82 | MAPT (0.70) | CYP2C19CYP3A4ALDH1A1POLBPARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1608339-B8 | PHARMACEUTICAL CO-CRYSTAL OF CELECOXIB-NICOTINAMIDE | MCNEIL PPC INC (US) | 2012-04-25 | — | — | EP | claimed |
| US-20070026078-A1 | Pharmaceutical co-crystal compositions | TRANSFORM PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | US | claimed |
| EP-1608339-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHIAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN | Transform Pharmaceuticals, Inc. (US) | 2005-12-28 | — | — | EP | claimed |
| WO-2004078161-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPTINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHIAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-09-16 | — | — | WO | claimed |
| CN-115554260-A | Effervescent composition comprising co-crystals of acid moieties | 布拉德福德大学 | 2023-01-03 | — | — | CN | disclosed |
| US-10420718-B2 | Effervescent compositions containing co-crystals of the acid part | UNIVERSITY OF BRADFORD (GB) | 2019-09-24 | — | — | US | disclosed |
| US-20170128359-A1 | EFFERVESCENT COMPOSITIONS CONTAINING CO-CRYSTALS OF THE ACID PART | UNIVERSITY OF BRADFORD (GB) | 2017-05-11 | — | — | US | disclosed |
| EP-3164116-A1 | EFFERVESCENT COMPOSITIONS CONTAINING CO-CRYSTALS OF THE ACID PART | University of Bradford (GB) | 2017-05-10 | — | — | EP | disclosed |
| WO-2016001681-A1 | EFFERVESCENT COMPOSITIONS CONTAINING CO-CRYSTALS OF THE ACID PART | UNIVERSITY OF BRADFORD (GB) | 2016-01-07 | — | — | WO | disclosed |
| EP-1608339-B8 | PHARMACEUTICAL CO-CRYSTAL OF CELECOXIB-NICOTINAMIDE | MCNEIL PPC INC (US) | 2012-04-25 | — | — | EP | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-20100311701-A1 | Pharmaceutical Co-Crystal Compositions | TRANSFORM PHARMACEUTICALS, INC (US) | 2010-12-09 | — | — | US | disclosed |
| US-20070059356-A1 | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen | REGENTS OF THE UNIVERSITY OF MICHIGAN, THE | 2007-03-15 | — | — | US | disclosed |
| US-20070026078-A1 | Pharmaceutical co-crystal compositions | TRANSFORM PHARMACEUTICALS, INC. (US) | 2007-02-01 | — | — | US | disclosed |
| EP-1608339-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHIAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN | Transform Pharmaceuticals, Inc. (US) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004078161-A1 | PHARMACEUTICAL CO-CRYSTAL COMPOSITIONS OF DRUGS SUCH AS CARBAMAZEPTINE, CELECOXIB, OLANZAPINE, ITRACONAZOLE, TOPIRAMATE, MODAFINIL, 5-FLUOROURACIL, HYDROCHLOROTHIAZIDE, ACETAMINOPHEN, ASPIRIN, FLURBIPROFEN, PHENYTOIN AND IBUPROFEN | TRANSFORM PHARMACEUTICALS, INC. (US) | 2004-09-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170128359-A1 | EFFERVESCENT COMPOSITIONS CONTAINING CO-CRYSTALS OF THE ACID PART | SLC11A2, NPC1L1, C9 | CYP2C19 3454/4885CYP1A2 3604/4885CYP2C9 2033/4885 |
| US-10420718-B2 | Effervescent compositions containing co-crystals of the acid part | C9, SLC11A2, NPC1L1 | CYP2C19 3105/4885CYP1A2 3232/4885CYP2C9 1735/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.